Who this is for
This page is for people with hormone receptor–positive, HER2-negative early breast cancer that has spread to one to three lymph nodes, and who are deciding whether chemotherapy is necessary.
Being told your cancer is “node-positive” often leads to the assumption that chemotherapy is unavoidable. For many years, that was true. The RxPONDER trial showed that the story is more nuanced — and that some patients with limited lymph node involvement may safely avoid chemotherapy depending on biological risk.
Why this question mattered
Historically, lymph node–positive breast cancer was treated more aggressively because nodal spread increased recurrence risk.
However, as genomic testing became more widely used, an important question emerged:
If a node-positive cancer has a low genomic recurrence score, does chemotherapy still add benefit?
RxPONDER was designed to answer that.
What RxPONDER studied
RxPONDER was a large, international, phase III clinical trial including over 5,000 women with:
• Hormone receptor–positive
• HER2-negative
• One to three positive lymph nodes
• Oncotype DX recurrence score of 25 or lower. (oncotype is genomic based test which is performed on the original biopsy/surgery specimen with no requirement for additional tissue or blood)
Participants were randomly assigned to:
• Endocrine therapy alone
• Chemotherapy plus endocrine therapy
The key analysis separated patients by menopausal status.
Key statistical results
• In postmenopausal women, invasive disease-free survival showed no significant benefit from chemotherapy (hazard ratio approximately 1.02).
• In premenopausal women, chemotherapy improved invasive disease-free survival (hazard ratio approximately 0.60).
• Five-year invasive disease-free survival in postmenopausal women was approximately 91% with endocrine therapy alone.
What this means
For postmenopausal women with one to three positive lymph nodes and a recurrence score of 25 or lower, chemotherapy did not meaningfully reduce recurrence risk.
In contrast, premenopausal women in the same genomic category did experience a benefit from chemotherapy.
This distinction is critical.
Node-positive status alone does not determine chemotherapy need.
Menopausal status and genomic risk both matters.
Why this matters in Melbourne and Australia
In Australia, genomic testing such as Oncotype DX is used selectively in hormone receptor–positive breast cancer to guide treatment decisions.
In Melbourne clinical practice, treatment discussions for node-positive disease often include:
• Number of positive nodes
• Recurrence score
• Menopausal status
• Tumour grade
• Patient preference
RxPONDER shifted the conversation from automatic chemotherapy to biologically guided decision-making.
That represents a major evolution in care.
Why this matters emotionally
For many patients, hearing “lymph node–positive” feels definitive.
RxPONDER showed that risk is layered.
For postmenopausal women with limited nodal involvement and low genomic risk, endocrine therapy alone may be sufficient.
That is not undertreatment.
It is precision treatment.
International patients, including Sri Lanka
Patients from Sri Lanka and other countries sometimes seek clarification about whether chemotherapy is necessary in node-positive disease.
Access to genomic testing may vary across healthcare systems. However, the biological principle established by RxPONDER applies broadly: nodal involvement should be interpreted alongside genomic risk and menopausal status.
A structured review of pathology and recurrence score can clarify the safest approach.
How RxPONDER fits with TAILORx
TAILORx addressed node-negative disease.
RxPONDER extended genomic-guided decision-making into selected node-positive patients.
Together, these trials reinforce an important shift:
Treatment intensity should reflect biological risk, not anatomy alone.
Key Takeaway
• In postmenopausal women with 1–3 positive lymph nodes and recurrence score ≤25, chemotherapy did not improve outcomes (hazard ratio ~1.02).
• Premenopausal women in the same genomic category did benefit from chemotherapy (hazard ratio ~0.60).
• Node-positive breast cancer is not uniform — genomic testing and menopausal status guide treatment decisions.